LUGPA Statement on Private Equity

January 2022

Private equity investment in healthcare has grown dramatically over the last decade, and urology groups nationwide are in the process of considering PE investments or have already elected to participate in PE platforms.  Member groups have asked about LUGPA’s position on these transactions.  To respond to these inquires, LUGPA’s Board of Directors has issued the following statement on Private Equity involvement in Independent Urology Groups.

LUGPA’s mission is to preserve and protect the independent practice of urology.  We consider the investment in member practices by private equity firms as a way for urology groups to remain independent of hospitals and health systems.  LUGPA neither endorses nor opposes private equity investments but relies on each of its member groups to evaluate the value of such transactions.  LUGPA does not endorse any private equity firm or holding company platform. 

LUGPA has longstanding conflict of interest and antitrust policies in place for its Board and committee members.  As private equity investment platforms continue to evolve, the Board and its nominating committee will continue to ensure broad representation from member groups when considering the composition of all LUGPA service positions.